Viking Therapeutics initiates VOYAGE study for VK2809 in NASH

Viking Therapeutics has initiated the VOYAGE study, a phase 2b clinical trial of its liver-selective thyroid hormone receptor beta agonist VK2809 in patients with biopsy-confirmed ... Read More